Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2023-12-31 | 1184004035 | u5 |
| ifrs-full:Assets | 2022-12-31 | 446733823 | u5 |
| ifrs-full:Assets | 2002-12-31 | 0 | u5 |
| ifrs-full:Assets | 2001-12-31 | 0 | u5 |
| ifrs-full:Assets | 2000-12-31 | 149608000 | u5 |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2023-01-01 | 2023-12-31 | 2017346469 | u5 |
| ifrs-full:Revenue | 2022-01-01 | 2022-12-31 | 509919862 | u5 |
| ifrs-full:Revenue | 2002-01-01 | 2002-12-31 | 0 | u5 |
| ifrs-full:Revenue | 2001-01-01 | 2001-12-31 | 0 | u5 |
| ifrs-full:Revenue | 2000-01-01 | 2000-12-31 | 363936000 | u5 |
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/54008183/amNsb3VkczovLzAzLzFkL2E3L2ViL2MxLzljZDYtNGM2MC1iOTcxLTgyMTU1Y2QyMWU3OA.xml
Separator
The full data:
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:g="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:f="http://xbrl.dcca.dk/arr" xmlns:d="http://xbrl.dcca.dk/cmn" xmlns:e="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"/><c:InformationOnTypeOfSubmittedReport contextRef="c1">Ã
rsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c1">34209936</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c1">Grant Thornton</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c1">Stockholmsgade 45</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c1">2100 København Ã</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:PrecedingReportingPeriodStartDate contextRef="c1">2022-01-01</c:PrecedingReportingPeriodStartDate><c:PredingReportingPeriodEndDate contextRef="c1">2022-12-31</c:PredingReportingPeriodEndDate><c:ReportingPeriodStartDate contextRef="c1">2023-01-01</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c1">2023-12-31</c:ReportingPeriodEndDate><c:IdentificationNumberCvrOfReportingEntity contextRef="c1">38180045</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c1">Novo Nordisk Denmark A/S</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c1">Kay Fiskers Plads</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c1">10, 7.</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c1">2300</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c1">København S</c:AddressOfReportingEntityDistrictName><c:DateOfFoundationOfReportingEntity contextRef="c1">2016-11-14</c:DateOfFoundationOfReportingEntity><c:RegisteredOfficeOfReportingEntity contextRef="c1">København</c:RegisteredOfficeOfReportingEntity><c:TelephoneNumberOfReportingEntity contextRef="c1">+45 35 35 00 02</c:TelephoneNumberOfReportingEntity><d:NameOfAuditFirm contextRef="c37">Deloitte, Statsautoriseret Revisionspartnerselskab</d:NameOfAuditFirm><d:NameOfAuditFirm contextRef="c38">Deloitte, Statsautoriseret Revisionspartnerselskab</d:NameOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c37">33963556</d:IdentificationNumberCvrOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c38">33963556</d:IdentificationNumberCvrOfAuditFirm><d:NameAndSurnameOfAuditor contextRef="c37">Sumit Sudan</d:NameAndSurnameOfAuditor><d:NameAndSurnameOfAuditor contextRef="c38">Ãzgün Acigora</d:NameAndSurnameOfAuditor><d:IdentificationNumberOfAuditor contextRef="c37">mne33716</d:IdentificationNumberOfAuditor><d:IdentificationNumberOfAuditor contextRef="c38">mne48478</d:IdentificationNumberOfAuditor><c:AddressOfAuditorStreetName contextRef="c37">Weidekampsgade</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetName contextRef="c38">Weidekampsgade</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c37">6</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c38">6</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c37">2300</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c38">2300</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c37">København S</c:AddressOfAuditorDistrictName><c:AddressOfAuditorDistrictName contextRef="c38">København S</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountry contextRef="c37">Danmark</c:AddressOfAuditorCountry><c:AddressOfAuditorCountry contextRef="c38">Danmark</c:AddressOfAuditorCountry><c:DateOfGeneralMeeting contextRef="c1">2024-05-21</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c1">Malin Eva Maria Andreasen</c:NameAndSurnameOfChairmanOfGeneralMeeting><e:ClassOfReportingEntity contextRef="c1">Regnskabsklasse C, stor virksomhed</e:ClassOfReportingEntity><d:TypeOfAuditorAssistance contextRef="c1">RevisionspÃ¥tegning</d:TypeOfAuditorAssistance><c:ToolForPreparingTheXBRLInstanceDocument contextRef="c1">CaseWare fra Revisorgruppen Danmark</c:ToolForPreparingTheXBRLInstanceDocument><f:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="c1">kapitalejeren</f:AddresseeOfAuditorsReportOnAuditedFinancialStatements><f:SignatureOfAuditorsPlace contextRef="c1">København S</f:SignatureOfAuditorsPlace><f:SignatureOfAuditorsDate contextRef="c1">2024-05-21</f:SignatureOfAuditorsDate><g:PlaceOfSignatureOfStatement contextRef="c1">Copenhagen</g:PlaceOfSignatureOfStatement><g:DateOfApprovalOfAnnualReport contextRef="c1">2024-05-21</g:DateOfApprovalOfAnnualReport><f:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="c1">Grundlag for konklusion</f:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements><f:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="c1">Konklusion</f:TypeOfModifiedOpinionOnAuditedFinancialStatements><e:Revenue contextRef="c1" unitRef="u5" decimals="0">2017346469</e:Revenue><e:Revenue contextRef="c2" unitRef="u5" decimals="0">509919862</e:Revenue><e:OtherOperatingIncome contextRef="c1" unitRef="u5" decimals="0">572245049</e:OtherOperatingIncome><e:OtherOperatingIncome contextRef="c2" unitRef="u5" decimals="0">457962345</e:OtherOperatingIncome><e:RawMaterialsAndConsumablesUsed contextRef="c1" unitRef="u5" decimals="0">1805069456</e:RawMaterialsAndConsumablesUsed><e:RawMaterialsAndConsumablesUsed contextRef="c2" unitRef="u5" decimals="0">380789376</e:RawMaterialsAndConsumablesUsed><e:OtherExternalExpenses contextRef="c1" unitRef="u5" decimals="0">311043278</e:OtherExternalExpenses><e:OtherExternalExpenses contextRef="c2" unitRef="u5" decimals="0">253920060</e:OtherExternalExpenses><e:GrossResult contextRef="c1" unitRef="u5" decimals="0">473478784</e:GrossResult><e:GrossResult contextRef="c2" unitRef="u5" decimals="0">333172771</e:GrossResult><e:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">362696623</e:EmployeeBenefitsExpense><e:EmployeeBenefitsExpense contextRef="c2" unitRef="u5" decimals="0">281181118</e:EmployeeBenefitsExpense><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c1" unitRef="u5" decimals="0">9762073</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c2" unitRef="u5" decimals="0">9361348</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c1" unitRef="u5" decimals="0">101020088</e:ProfitLossFromOrdinaryOperatingActivities><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c2" unitRef="u5" decimals="0">42630305</e:ProfitLossFromOrdinaryOperatingActivities><e:OtherFinanceIncome contextRef="c1" unitRef="u5" decimals="0">9715586</e:OtherFinanceIncome><e:OtherFinanceIncome contextRef="c2" unitRef="u5" decimals="0">2356913</e:OtherFinanceIncome><e:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">2823959</e:OtherFinanceExpenses><e:OtherFinanceExpenses contextRef="c2" unitRef="u5" decimals="0">952921</e:OtherFinanceExpenses><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c1" unitRef="u5" decimals="0">107911715</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c2" unitRef="u5" decimals="0">44034297</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:TaxExpense contextRef="c1" unitRef="u5" decimals="0">25914102</e:TaxExpense><e:TaxExpense contextRef="c2" unitRef="u5" decimals="0">10486393</e:TaxExpense><e:ProfitLoss contextRef="c1" unitRef="u5" decimals="0">81997613</e:ProfitLoss><e:ProfitLoss contextRef="c2" unitRef="u5" decimals="0">33547904</e:ProfitLoss><e:ProposedDividendRecognisedInEquity contextRef="c4" unitRef="u5" decimals="0">82000000</e:ProposedDividendRecognisedInEquity><e:ProposedDividendRecognisedInEquity contextRef="c3" unitRef="u5" decimals="0">33500000</e:ProposedDividendRecognisedInEquity><e:TransferredToFromRetainedEarnings contextRef="c1" unitRef="u5" decimals="0">-2387</e:TransferredToFromRetainedEarnings><e:TransferredToFromRetainedEarnings contextRef="c2" unitRef="u5" decimals="0">47904</e:TransferredToFromRetainedEarnings><e:LandAndBuildings contextRef="c4" unitRef="u5" decimals="0">21396117</e:LandAndBuildings><e:LandAndBuildings contextRef="c3" unitRef="u5" decimals="0">17029009</e:LandAndBuildings><e:FixturesFittingsToolsAndEquipment contextRef="c4" unitRef="u5" decimals="0">17461609</e:FixturesFittingsToolsAndEquipment><e:FixturesFittingsToolsAndEquipment contextRef="c3" unitRef="u5" decimals="0">12497381</e:FixturesFittingsToolsAndEquipment><e:LeaseholdImprovements contextRef="c4" unitRef="u5" decimals="0">353480</e:LeaseholdImprovements><e:LeaseholdImprovements contextRef="c3" unitRef="u5" decimals="0">443730</e:LeaseholdImprovements><e:PropertyPlantAndEquipment contextRef="c4" unitRef="u5" decimals="0">39211206</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c3" unitRef="u5" decimals="0">29970120</e:PropertyPlantAndEquipment><e:NoncurrentAssets contextRef="c4" unitRef="u5" decimals="0">39211206</e:NoncurrentAssets><e:NoncurrentAssets contextRef="c3" unitRef="u5" decimals="0">29970120</e:NoncurrentAssets><e:ShorttermTradeReceivables contextRef="c4" unitRef="u5" decimals="0">383268074</e:ShorttermTradeReceivables><e:ShorttermTradeReceivables contextRef="c3" unitRef="u5" decimals="0">97701713</e:ShorttermTradeReceivables><e:ShorttermReceivablesFromGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">687738720</e:ShorttermReceivablesFromGroupEnterprises><e:ShorttermReceivablesFromGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">306302454</e:ShorttermReceivablesFromGroupEnterprises><e:CurrentDeferredTaxAssets contextRef="c4" unitRef="u5" decimals="0">11184068</e:CurrentDeferredTaxAssets><e:CurrentDeferredTaxAssets contextRef="c3" unitRef="u5" decimals="0">7912426</e:CurrentDeferredTaxAssets><e:OtherShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">59088386</e:OtherShorttermReceivables><e:OtherShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">2978</e:OtherShorttermReceivables><e:DeferredIncomeAssets contextRef="c4" unitRef="u5" decimals="0">3513581</e:DeferredIncomeAssets><e:DeferredIncomeAssets contextRef="c3" unitRef="u5" decimals="0">4844132</e:DeferredIncomeAssets><e:ShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">1144792829</e:ShorttermReceivables><e:ShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">416763703</e:ShorttermReceivables><e:CurrentAssets contextRef="c4" unitRef="u5" decimals="0">1144792829</e:CurrentAssets><e:CurrentAssets contextRef="c3" unitRef="u5" decimals="0">416763703</e:CurrentAssets><e:Assets contextRef="c4" unitRef="u5" decimals="0">1184004035</e:Assets><e:Assets contextRef="c3" unitRef="u5" decimals="0">446733823</e:Assets><e:RecognisedButNotOwnedAssets contextRef="c1" unitRef="u5" decimals="0">33446568</e:RecognisedButNotOwnedAssets><e:ContributedCapital contextRef="c4" unitRef="u5" decimals="0">500000</e:ContributedCapital><e:ContributedCapital contextRef="c3" unitRef="u5" decimals="0">500000</e:ContributedCapital><e:RetainedEarnings contextRef="c4" unitRef="u5" decimals="0">15138061</e:RetainedEarnings><e:RetainedEarnings contextRef="c3" unitRef="u5" decimals="0">15140448</e:RetainedEarnings><e:ProposedDividendRecognisedInEquity contextRef="c4" unitRef="u5" decimals="0">82000000</e:ProposedDividendRecognisedInEquity><e:ProposedDividendRecognisedInEquity contextRef="c3" unitRef="u5" decimals="0">33500000</e:ProposedDividendRecognisedInEquity><e:Equity contextRef="c4" unitRef="u5" decimals="0">97638061</e:Equity><e:Equity contextRef="c3" unitRef="u5" decimals="0">49140448</e:Equity><e:OtherProvisions contextRef="c4" unitRef="u5" decimals="0">44897615</e:OtherProvisions><e:OtherProvisions contextRef="c3" unitRef="u5" decimals="0">38071560</e:OtherProvisions><e:Provisions contextRef="c4" unitRef="u5" decimals="0">44897615</e:Provisions><e:Provisions contextRef="c3" unitRef="u5" decimals="0">38071560</e:Provisions><e:LongtermLeaseCommitments contextRef="c4" unitRef="u5" decimals="0">29881568</e:LongtermLeaseCommitments><e:LongtermLeaseCommitments contextRef="c3" unitRef="u5" decimals="0">20612994</e:LongtermLeaseCommitments><e:LongtermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">29881568</e:LongtermLiabilitiesOtherThanProvisions><e:LongtermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">20612994</e:LongtermLiabilitiesOtherThanProvisions><e:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">6677515</e:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions><e:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">6605043</e:ShorttermPartOfLongtermLiabilitiesOtherThanProvisions><e:ShorttermTradePayables contextRef="c4" unitRef="u5" decimals="0">33345109</e:ShorttermTradePayables><e:ShorttermTradePayables contextRef="c3" unitRef="u5" decimals="0">20501974</e:ShorttermTradePayables><e:ShorttermPayablesToGroupEnterprises contextRef="c4" unitRef="u5" decimals="0">823619295</e:ShorttermPayablesToGroupEnterprises><e:ShorttermPayablesToGroupEnterprises contextRef="c3" unitRef="u5" decimals="0">196341712</e:ShorttermPayablesToGroupEnterprises><e:ShorttermTaxPayables contextRef="c4" unitRef="u5" decimals="0">26544744</e:ShorttermTaxPayables><e:ShorttermTaxPayables contextRef="c3" unitRef="u5" decimals="0">7962535</e:ShorttermTaxPayables><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c4" unitRef="u5" decimals="0">121400128</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c3" unitRef="u5" decimals="0">107497557</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">1011586791</e:ShorttermLiabilitiesOtherThanProvisions><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">338908821</e:ShorttermLiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">1041468359</e:LiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">359521815</e:LiabilitiesOtherThanProvisions><e:LiabilitiesAndEquity contextRef="c4" unitRef="u5" decimals="0">1184004035</e:LiabilitiesAndEquity><e:LiabilitiesAndEquity contextRef="c3" unitRef="u5" decimals="0">446733823</e:LiabilitiesAndEquity><e:WagesAndSalaries contextRef="c1" unitRef="u5" decimals="0">337707526</e:WagesAndSalaries><e:WagesAndSalaries contextRef="c2" unitRef="u5" decimals="0">261414986</e:WagesAndSalaries><e:PostemploymentBenefitExpense contextRef="c1" unitRef="u5" decimals="0">23813996</e:PostemploymentBenefitExpense><e:PostemploymentBenefitExpense contextRef="c2" unitRef="u5" decimals="0">18004573</e:PostemploymentBenefitExpense><e:SocialSecurityContributions contextRef="c1" unitRef="u5" decimals="0">1175101</e:SocialSecurityContributions><e:SocialSecurityContributions contextRef="c2" unitRef="u5" decimals="0">1761559</e:SocialSecurityContributions><e:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">362696623</e:EmployeeBenefitsExpense><e:EmployeeBenefitsExpense contextRef="c2" unitRef="u5" decimals="0">281181118</e:EmployeeBenefitsExpense><e:AverageNumberOfEmployees contextRef="c1" unitRef="u7" decimals="INF">236</e:AverageNumberOfEmployees><e:AverageNumberOfEmployees contextRef="c2" unitRef="u7" decimals="INF">200</e:AverageNumberOfEmployees><e:InterestExpenseAssignedToGroupEnterprises contextRef="c1" unitRef="u5" decimals="0">580021</e:InterestExpenseAssignedToGroupEnterprises><e:InterestExpenseAssignedToGroupEnterprises contextRef="c2" unitRef="u5" decimals="0">306787</e:InterestExpenseAssignedToGroupEnterprises><e:OtherInterestExpenses contextRef="c1" unitRef="u5" decimals="0">2243938</e:OtherInterestExpenses><e:OtherInterestExpenses contextRef="c2" unitRef="u5" decimals="0">646134</e:OtherInterestExpenses><e:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">2823959</e:OtherFinanceExpenses><e:OtherFinanceExpenses contextRef="c2" unitRef="u5" decimals="0">952921</e:OtherFinanceExpenses><e:PropertyPlantAndEquipmentGross contextRef="c84" unitRef="u5" decimals="0">17317474</e:PropertyPlantAndEquipmentGross><e:AdditionsToPropertyPlantAndEquipment contextRef="c88" unitRef="u5" decimals="0">8387538</e:AdditionsToPropertyPlantAndEquipment><e:PropertyPlantAndEquipmentGross contextRef="c89" unitRef="u5" decimals="0">25705012</e:PropertyPlantAndEquipmentGross><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c84" unitRef="u5" decimals="0">288464</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:DepreciationOfPropertyPlantAndEquipment contextRef="c88" unitRef="u5" decimals="0">4020431</e:DepreciationOfPropertyPlantAndEquipment><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c89" unitRef="u5" decimals="0">4308895</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c89" unitRef="u5" decimals="0">21396117</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipmentGross contextRef="c99" unitRef="u5" decimals="0">22174588</e:PropertyPlantAndEquipmentGross><e:AdditionsToPropertyPlantAndEquipment contextRef="c100" unitRef="u5" decimals="0">10615620</e:AdditionsToPropertyPlantAndEquipment><e:DisposalsOfPropertyPlantAndEquipment contextRef="c100" unitRef="u5" decimals="0">2693236</e:DisposalsOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipmentGross contextRef="c101" unitRef="u5" decimals="0">30096972</e:PropertyPlantAndEquipmentGross><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c99" unitRef="u5" decimals="0">9677207</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:DepreciationOfPropertyPlantAndEquipment contextRef="c100" unitRef="u5" decimals="0">5651392</e:DepreciationOfPropertyPlantAndEquipment><e:ReversalsOfImpairmentLossesAndDepreciationOfDisposedPropertyPlantAndEquipment contextRef="c100" unitRef="u5" decimals="0">2693236</e:ReversalsOfImpairmentLossesAndDepreciationOfDisposedPropertyPlantAndEquipment><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c101" unitRef="u5" decimals="0">12635363</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c101" unitRef="u5" decimals="0">17461609</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipmentGross contextRef="c105" unitRef="u5" decimals="0">451251</e:PropertyPlantAndEquipmentGross><e:PropertyPlantAndEquipmentGross contextRef="c107" unitRef="u5" decimals="0">451251</e:PropertyPlantAndEquipmentGross><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c105" unitRef="u5" decimals="0">7521</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:DepreciationOfPropertyPlantAndEquipment contextRef="c106" unitRef="u5" decimals="0">90250</e:DepreciationOfPropertyPlantAndEquipment><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c107" unitRef="u5" decimals="0">97771</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c107" unitRef="u5" decimals="0">353480</e:PropertyPlantAndEquipment><e:LongtermLiabilitiesOtherThanProvisionsDueInOneYear contextRef="c254" unitRef="u5" decimals="0">6677515</e:LongtermLiabilitiesOtherThanProvisionsDueInOneYear><e:LongtermLiabilitiesOtherThanProvisionsDueAfterFiveYearsAndMore contextRef="c254" unitRef="u5" decimals="0">0</e:LongtermLiabilitiesOtherThanProvisionsDueAfterFiveYearsAndMore><e:Equity contextRef="c119" unitRef="u5" decimals="0">500000</e:Equity><e:Equity contextRef="c478" unitRef="u5" decimals="0">500000</e:Equity><e:Equity contextRef="c121" unitRef="u5" decimals="0">500000</e:Equity><e:Equity contextRef="c480" unitRef="u5" decimals="0">500000</e:Equity><e:Equity contextRef="c137" unitRef="u5" decimals="0">15140448</e:Equity><e:Equity contextRef="c498" unitRef="u5" decimals="0">15092544</e:Equity><e:ProfitLoss contextRef="c138" unitRef="u5" decimals="0">-2387</e:ProfitLoss><e:ProfitLoss contextRef="c499" unitRef="u5" decimals="0">47904</e:ProfitLoss><e:Equity contextRef="c139" unitRef="u5" decimals="0">15138061</e:Equity><e:Equity contextRef="c500" unitRef="u5" decimals="0">15140448</e:Equity><e:Equity contextRef="c140" unitRef="u5" decimals="0">33500000</e:Equity><e:Equity contextRef="c501" unitRef="u5" decimals="0">21400000</e:Equity><e:DividendPaid contextRef="c141" unitRef="u5" decimals="0">33500000</e:DividendPaid><e:DividendPaid contextRef="c502" unitRef="u5" decimals="0">21400000</e:DividendPaid><e:Dividend contextRef="c141" unitRef="u5" decimals="0">82000000</e:Dividend><e:Dividend contextRef="c502" unitRef="u5" decimals="0">33500000</e:Dividend><e:Equity contextRef="c142" unitRef="u5" decimals="0">82000000</e:Equity><e:Equity contextRef="c503" unitRef="u5" decimals="0">33500000</e:Equity><g:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="en">Today, the Board of Directors and the Managing Director have approved the annual report of Novo Nordisk Denmark A/S for the financial year 1 January - 31 December 2023.
</g:IdentificationOfApprovedAnnualReport><g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="en">The annual report has been prepared in accordance with the Danish Financial Statements Act.
</g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="en">We consider the chosen accounting policy to be appropriate, and in our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January â 31 December 2023.
</g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><g:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="en">Further, in our opinion, the Management's Review gives a true and fair review of the matters discussed in the Management's Review.
</g:ManagementsStatementAboutManagementsReview><g:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="en">We recommend that the annual report be approved at the Annual General Meeting.
</g:RecommendationForApprovalOfAnnualReportByGeneralMeeting><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c29">Jeppe Theisen</d:NameAndSurnameOfMemberOfExecutiveBoard><d:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c5">Jonas Emil Kongshøj Larsen</d:NameAndSurnameOfMemberOfSupervisoryBoard><d:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c6">Malin Eva Maria Andreasen</d:NameAndSurnameOfMemberOfSupervisoryBoard><d:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c7">Anders Rytter Mikkelsen</d:NameAndSurnameOfMemberOfSupervisoryBoard><f:OpinionOnAuditedFinancialStatements contextRef="c1" xml:lang="en">We have audited the financial statements of Novo Nordisk Denmark A/S for the financial year 1 January - 31 December 2023, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes, for the Company. The financial statements are prepared with the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2023, and of the results of the it's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.
</f:OpinionOnAuditedFinancialStatements><f:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="c1" xml:lang="en">Basis for conclusion
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the âAuditorâs Responsibilities for the Audit of the Financial Statementsâ section of this auditor's report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
</f:DescriptionOfQualificationsOfAuditedFinancialStatements><f:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="c1" xml:lang="en">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, for disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
</f:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements><f:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="c1" xml:lang="en">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Companyâs internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
Conclude on the appropriateness of Managementâs use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Companyâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Company to cease to continue as a going concern.
Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
</f:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed><f:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="c1" xml:lang="en">Statement on Managementâs Review
Management is responsible for Managementâs Review.
Our opinion on the financial statements does not cover Managementâs Review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read Managementâs Review and, in doing so, consider whether Managementâs Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether Managementâs Review provides the information required by relevant law and regulations.
Based on the work we have performed, we conclude that Managementâs Review is in accordance with the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of Managementâs Review.
</f:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements><e:Revenue contextRef="c184" unitRef="u5" decimals="-3">0</e:Revenue><e:Revenue contextRef="c187" unitRef="u5" decimals="-3">0</e:Revenue><e:Revenue contextRef="c190" unitRef="u5" decimals="-3">363936000</e:Revenue><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c184" unitRef="u5" decimals="-3">0</e:ProfitLossFromOrdinaryOperatingActivities><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c187" unitRef="u5" decimals="-3">0</e:ProfitLossFromOrdinaryOperatingActivities><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c190" unitRef="u5" decimals="-3">8811000</e:ProfitLossFromOrdinaryOperatingActivities><e:ResultsFromNetFinancials contextRef="c1" unitRef="u5" decimals="-3">-6892000</e:ResultsFromNetFinancials><e:ResultsFromNetFinancials contextRef="c2" unitRef="u5" decimals="-3">-1404000</e:ResultsFromNetFinancials><e:ResultsFromNetFinancials contextRef="c184" unitRef="u5" decimals="-3">1586000</e:ResultsFromNetFinancials><e:ResultsFromNetFinancials contextRef="c187" unitRef="u5" decimals="-3">200000</e:ResultsFromNetFinancials><e:ResultsFromNetFinancials contextRef="c190" unitRef="u5" decimals="-3">-511000</e:ResultsFromNetFinancials><e:ProfitLoss contextRef="c184" unitRef="u5" decimals="-3">0</e:ProfitLoss><e:ProfitLoss contextRef="c187" unitRef="u5" decimals="-3">0</e:ProfitLoss><e:ProfitLoss contextRef="c190" unitRef="u5" decimals="-3">5252000</e:ProfitLoss><e:Assets contextRef="c186" unitRef="u5" decimals="-3">0</e:Assets><e:Assets contextRef="c189" unitRef="u5" decimals="-3">0</e:Assets><e:Assets contextRef="c192" unitRef="u5" decimals="-3">149608000</e:Assets><e:InvestmentInPropertyPlantAndEquipment contextRef="c1" unitRef="u5" decimals="-3">19003000</e:InvestmentInPropertyPlantAndEquipment><e:InvestmentInPropertyPlantAndEquipment contextRef="c2" unitRef="u5" decimals="-3">23612000</e:InvestmentInPropertyPlantAndEquipment><e:InvestmentInPropertyPlantAndEquipment contextRef="c184" unitRef="u5" decimals="-3">4375000</e:InvestmentInPropertyPlantAndEquipment><e:InvestmentInPropertyPlantAndEquipment contextRef="c187" unitRef="u5" decimals="-3">29050000</e:InvestmentInPropertyPlantAndEquipment><e:InvestmentInPropertyPlantAndEquipment contextRef="c190" unitRef="u5" decimals="-3">0</e:InvestmentInPropertyPlantAndEquipment><e:Equity contextRef="c186" unitRef="u5" decimals="-3">0</e:Equity><e:Equity contextRef="c189" unitRef="u5" decimals="-3">0</e:Equity><e:Equity contextRef="c192" unitRef="u5" decimals="-3">15343000</e:Equity><e:AverageNumberOfEmployees contextRef="c184" unitRef="u7" decimals="INF">0</e:AverageNumberOfEmployees><e:AverageNumberOfEmployees contextRef="c187" unitRef="u7" decimals="INF">0</e:AverageNumberOfEmployees><e:AverageNumberOfEmployees contextRef="c190" unitRef="u7" decimals="INF">65</e:AverageNumberOfEmployees><h:OperatingMargin contextRef="c1" unitRef="u7" decimals="1">5</h:OperatingMargin><h:OperatingMargin contextRef="c2" unitRef="u7" decimals="1">8.4</h:OperatingMargin><h:OperatingMargin contextRef="c184" unitRef="u7" decimals="1">8.1</h:OperatingMargin><h:OperatingMargin contextRef="c187" unitRef="u7" decimals="1">8.5</h:OperatingMargin><h:OperatingMargin contextRef="c190" unitRef="u7" decimals="1">2.4</h:OperatingMargin><h:GrossMargin contextRef="c1" unitRef="u7" decimals="1">23.5</h:GrossMargin><h:GrossMargin contextRef="c2" unitRef="u7" decimals="1">65.3</h:GrossMargin><h:GrossMargin contextRef="c184" unitRef="u7" decimals="1">79.9</h:GrossMargin><h:GrossMargin contextRef="c187" unitRef="u7" decimals="1">75.5</h:GrossMargin><h:GrossMargin contextRef="c190" unitRef="u7" decimals="1">33.5</h:GrossMargin><h:NameOfKeyFigureOrFinancialRatio contextRef="c381">Egen tekst her</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c382">Egen tekst her</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c383">Egen tekst her</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c384">Egen tekst her</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c385">Egen tekst her</h:NameOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c381" unitRef="u7" decimals="2">5.5</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c382" unitRef="u7" decimals="2">10.3</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c383" unitRef="u7" decimals="2">10.7</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c384" unitRef="u7" decimals="2">11.3</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c385" unitRef="u7" decimals="2">2.5</h:ValueOfKeyFigureOrFinancialRatio><h:ReturnOnInvestedCapital contextRef="c1" unitRef="u7" decimals="1">12.4</h:ReturnOnInvestedCapital><h:ReturnOnInvestedCapital contextRef="c2" unitRef="u7" decimals="1">11.7</h:ReturnOnInvestedCapital><h:ReturnOnInvestedCapital contextRef="c184" unitRef="u7" decimals="1">7</h:ReturnOnInvestedCapital><h:ReturnOnInvestedCapital contextRef="c187" unitRef="u7" decimals="1">7.7</h:ReturnOnInvestedCapital><h:ReturnOnInvestedCapital contextRef="c190" unitRef="u7" decimals="1">6.3</h:ReturnOnInvestedCapital><h:NameOfKeyFigureOrFinancialRatio contextRef="c331">Likviditetsgrad</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c332">Likviditetsgrad</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c333">Likviditetsgrad</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c334">Likviditetsgrad</h:NameOfKeyFigureOrFinancialRatio><h:NameOfKeyFigureOrFinancialRatio contextRef="c335">Likviditetsgrad</h:NameOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c331" unitRef="u7" decimals="INF">113.2</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c332" unitRef="u7" decimals="INF">123</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c333" unitRef="u7" decimals="INF">131.4</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c334" unitRef="u7" decimals="INF">107.6</h:ValueOfKeyFigureOrFinancialRatio><h:ValueOfKeyFigureOrFinancialRatio contextRef="c335" unitRef="u7" decimals="INF">111.5</h:ValueOfKeyFigureOrFinancialRatio><h:ReturnOnEquity contextRef="c1" unitRef="u7" decimals="1">111.7</h:ReturnOnEquity><h:ReturnOnEquity contextRef="c2" unitRef="u7" decimals="1">77.9</h:ReturnOnEquity><h:ReturnOnEquity contextRef="c184" unitRef="u7" decimals="1">58.2</h:ReturnOnEquity><h:ReturnOnEquity contextRef="c187" unitRef="u7" decimals="1">81.9</h:ReturnOnEquity><h:ReturnOnEquity contextRef="c190" unitRef="u7" decimals="1">41.3</h:ReturnOnEquity><h:EquityRatio contextRef="c1" unitRef="u7" decimals="1">8.2</h:EquityRatio><h:EquityRatio contextRef="c2" unitRef="u7" decimals="1">11</h:EquityRatio><h:EquityRatio contextRef="c184" unitRef="u7" decimals="1">13.1</h:EquityRatio><h:EquityRatio contextRef="c187" unitRef="u7" decimals="1">6.3</h:EquityRatio><h:EquityRatio contextRef="c190" unitRef="u7" decimals="1">10.3</h:EquityRatio><e:DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview contextRef="c1" xml:lang="en">The key figures appearing from the survey have been calculated as follows:
Operating margin Operating profit (EBIT) x 100 / Revenue
Gross margin ratio Gross margin x 100 / Revenue
EBITDA margin Earnings before interest, taxes and amortisations x 100 / Revenue
Return on assets Results from primary activities (EBIT) x 100
Current ratio Current assets x 100 / Short term liabilities
Equity ratio Equity, closing balance x 100 / Total assets, closing balance
Return on equity Results for the year x 100 / Average equity</e:DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c1" xml:lang="en">Business review
Novo Nordisk Denmark A/S (secondary name Novo Nordisk Region Europe Pharmaceuticals A/S and Novo Nordisk North West Europe Pharmaceuticals A/S) is selling medicine in the treatment areas diabetes, obesity, rare endocrine and blood disorders as well as hormone replacement treatment. The company is located in Ãrestad in Copenhagen, Denmark. Number of average employees has increased from 200 in 2022 to 236 in 2023. Novo Nordisk Denmark A/S consist of the following three business units: The Danish sales affiliate The unit is a fully operational sales affiliate with focus on the distribution of the medicine produced by Novo Nordisk A/S and Novo Nordisk Healthcare AG to patients in Denmark and Iceland. Novo Nordisk A/S and Novo Nordisk Healthcare AG bears all the risks for launches as well as research and development, hence launch costs and R&D costs are invoiced to Novo Nordisk A/S and Novo Nordisk Healthcare AG as service fee including a mark-up for internal costs. North West Europe regional office Service company supporting the business areas/large affiliates in Europe such as UK, France, Spain, Switzerland, Netherlands, Denmark, Sweden and business area North West Europe mid-size (Norway, Finland, Belgium, Austria, Portugal and Ireland). All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs. North West Europe mid size business area office Service company supporting the affiliates in business area North West Europe mid-size (Norway, Finland, Belgium, Austria, Portugal and Ireland). All costs, both internal and external are invoiced to the affiliates in business area NWE mid-size and to Novo Nordisk A/S. All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs.
</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfAnyUnusualMattersAffectingRecognitionOrMeasurement contextRef="c1" xml:lang="en">Unusual matters having affected the financial statements
No unusual matters has effected the financial statements for 2023.
</h:DescriptionOfAnyUnusualMattersAffectingRecognitionOrMeasurement><h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c1" xml:lang="en">Development in activities and financial matters
The revenue for the year totals 2.017.346 tDKK against 509.920 tDKK last year. Net profit from the year totals 81.998 tDKK against 33.547 tDKK last year. The revenue growth in 2023 (+1.507.427 tDKK) was driven by Ozempic® and Wegovy® primarily. There was a high growth of patients receiving Ozempic® and a larger share of the Ozempic® sales was covered by Novo Nordisk Denmark due to lower levels of Ozempic® import, overall, this resulted in a sales growth of 653.236 tDKK for Ozempic®. The launch of Wegovy® was also a key driver of growth in 2023 contributing with +851.630 tDKK growth versus 2022. The full year staff cost was 362.696 tDKK against 281.181 tDKK last year. The increasing cost base was a result of higher capacity cost driven by an increase in the manning by 36 FTE versus 2022 to a total of 236 FTE. The higher manning was primarily related to the clinical and medical expansions including Clinical Development Center (+ 24 FTE versus 2022). Overall direct marketing Investments increased to DKK 97.895 tDKK in 2023 vs. DKK 87.577 tDKK last year. The marketing investment were primarily allocated to Rybelsus® and Wegovy®.
The financial position at 31 December 2023 has been significantly impacted by growth in the semaglutide portfolio with extraordinary results from the launch of Wegovy® in January 2023 and continued growth of Ozempic. Additionally, Ozempic sales in Denmark have been subject to significantly less parallel trade versus previous years, sales which are picked up by Novo Nordisk Denmark.
</h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><h:DescriptionOfExpectedDevelopment contextRef="c1" xml:lang="en">Outlook
Sales and cost in 2024 are expected to be at a similar level to 2023 with a net profit between 70.000-80.000 tDKK, however, the GLP-1a portfolio for both diabetes and obesity is expected to constitute an increasingly larger share of the sales (in 2024 GLP-1a will account for 86% of the sales which equates to an increase of +5%p versus last year). Direct marketing investments will be focused on Rybelsus® and Wegovy® in 2024. The FTE base is not expected to grow substantially in 2024.
For further information on products in pipeline and other developments areas, please read the annual report for the Novo Nordisk Group.
</h:DescriptionOfExpectedDevelopment><h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="c1" xml:lang="en">Events occurring after the end of the financial year
There have been no events after the financial year that affect the company's financial position.
</h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod><h:StatementOfCorporateSocialResponsibility contextRef="c1" xml:lang="en">Corporate social responsibility report and report of data ethics according to section 99a and 99d of the Danish Financial Statements Act
Information on CSR
By reference to section 99a (7) of the Danish Financial Statements Act, corporate social responsibility report is disclosed in the annual report for Novo Nordisk A/S. By reference to section 99d (3) of the Danish Financial Statements Act, data ethics are also disclosed in the annual report for Novo Nordisk A/S. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf
</h:StatementOfCorporateSocialResponsibility><h:TotalNumberOfMembersOfBoardOfDirectorsExcludingEmployeeelectedMembers contextRef="c4" unitRef="u7" decimals="INF">3</h:TotalNumberOfMembersOfBoardOfDirectorsExcludingEmployeeelectedMembers><h:PercentageOfUnderrepresentedGenderBoardOfDirectors contextRef="c4" unitRef="u7" decimals="1">0</h:PercentageOfUnderrepresentedGenderBoardOfDirectors><h:TargetFigureInPercentageOfUnderrepresentedGenderBoardOfDirectors contextRef="c4" unitRef="u7" decimals="1">45</h:TargetFigureInPercentageOfUnderrepresentedGenderBoardOfDirectors><h:YearOfFulfillmentOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors contextRef="c4">2025</h:YearOfFulfillmentOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors><h:TotalNumberOfOtherManagementLevels contextRef="c4" unitRef="u7" decimals="INF">8</h:TotalNumberOfOtherManagementLevels><h:PercentageOfUnderrepresentedGenderOtherManagementLevels contextRef="c4" unitRef="u7" decimals="1">50</h:PercentageOfUnderrepresentedGenderOtherManagementLevels><h:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender contextRef="c1" xml:lang="en">In April 2024, changes in BoD has been done and a woman has been elected.
Target figures for the companyâs top management
During 2023, Novo Nordisk Denmark A/S has been working to improve and maintain a sustainable approach to the well-being of the employees, with a strive for a diverse and inclusive working place. All employees should feel a sense of belonging and have the opportunities to realize their potential.
By reference to section 99b in the Financial Statements Act (the underrepresented gender), at the end of 2023, the Board consisted of three male shareholder-elected Board members. During 2023 there has been no changes in the structure of BoD or in the positions that is applicable for the members (SVP of Region North West Europe, General Manager of the Danish Sales Affiliate and CVP of Finance & Operations in Region North West Europe). The Board therefore continues to pursue the target of including more female Board members.
Management in Novo Nordisk Denmark A/S is characterized by managers, directors, vice presidents, corporate vice presidents and one senior vice president. As of 31 December 2023, the share of the underrepresented gender in the Board of Directors at Novo Nordisk Denmark A/S is 0% and have achieved a 50% representation for other management. Other management in this report are people managers reporting directly to the SVP of Region North West Europe. Novo Nordisk globally has a target of achieving a minimum 45% representation at an upper management level and are striving towards a balanced gender ration at all other levels of management. At Novo Nordisk Denmark A/S we have achieved equal gender representation with our other management level. Key actions in 2023 have been to ensure that the company has robust succession planning across each of the areas and a equitable, fair and open approach to recruitment.
Policies for the companyâs other management levels
For additional information please refer to the Novo Nordisk A/S gender and diversity policies which can be found on the Novo Nordisk ESG portal: https://www.novonordisk.com/sustainable-business/esg-portal.html
Novo Nordisk Denmark A/S focuses on three specific primary drivers in the gender and diversity agenda locally: Mitigating bias, creating an inclusive workplace and having leaders serve as role models. Its most significant activities include yearly equal pay reviews, a gender neutral parental leave policy, tracking of gender representation across all managerial levels and aspirational gender diversity targets of at least 45% of underrepresented gender in managerial positions.
</h:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="en">The annual report for Novo Nordisk Denmark A/S has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class C enterprises (large enterprises).
The accounting policies are unchanged from last year, and the annual report is presented in DKK.
According to section 96 (3) of the Danish Financial Statements Act, the company has not disclosed the fee to the auditor, as the relevant information is included in the consolidated Financial Statements of Novo Nordisk A/S.
</e:InformationOnReportingClassOfEntity><e:ExplanationOfNotDisclosingCashFlowsStatements contextRef="c1" xml:lang="en">Pursuant to section 86 (4) of the Danish Financial Statements Act, no statement of cash flows for the enterprise has been prepared, as the relevant information is included in the consolidated financial statements of Novo Nordisk A/S.
</e:ExplanationOfNotDisclosingCashFlowsStatements><e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1" xml:lang="en">Recognition and measurement in general
Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, writedowns for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.
Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.
Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.
Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.
Upon recognition and measurement, allowances are made for such predictable losses and risks which may arise prior to the presentation of the annual report and concern matters that exist on the reporting date.
</e:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><e:DescriptionOfMethodsOfForeignCurrencies contextRef="c1" xml:lang="en">Foreign currency translation
Transactions in foreign currency are translated by using the exchange rate prevailing at the date of the transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under net financials.
Receivables, payables, and other foreign currency monetary items are translated using the closing rate. The difference between the closing rate and the rate at the time of the occurrence or initial recognition in the latest Financial Statements of the receivable or payable is recognised in the income statement under financial income and expenses.
</e:DescriptionOfMethodsOfForeignCurrencies><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c1" xml:lang="en">Revenue
The enterprise is applying IFRS 15 as its basis of interpretation for the recognition of revenue.
Revenue consist of the net sales of pharmaceutical products sold to patients.
Revenue from sale of goods is recognised when Novo Nordisk Denmark A/S has transferred control of products sold to the buyer and it is probable that Novo Nordisk Denmark A/S will collect the consideration to which it is entitled for transferring the products.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncome contextRef="c1" xml:lang="en">Other operating income
Other operating income is related to invoiced service fees to Novo Nordisk A/S and Novo Nordisk Healthcare AG which consist of the income from the rendering of services is recognised as revenue as the services are rendered.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncome><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="c1" xml:lang="en">Cost of sales
Cost of sales comprises costs concerning purchase of finished goods and consumables less discounts.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="en">Other external expenses
Other external expenses comprise expenses incurred for distribution, sales, advertising, administration, premises and loss on receivables.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="c1" xml:lang="en">Staff costs
Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members. Staff costs are less public reimbursements.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense><e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="c1" xml:lang="en">Depreciation, amortisation and writedown
Depreciation, amortisation and writedown comprise depreciation on, amortisation of and writedown relating to tangible fixed assets.
</e:DescriptionOfMethodsOfImpairmentLossesAndDepreciation><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="c1" xml:lang="en">Financial income and expenses
Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses, financial expenses from financial leasing and reimbursements under the advance tax scheme, etc.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="en">Tax on net profit or loss for the year
The tax for the year comprises the current tax for the year and the changes in deferred tax, and it is recognised in the profit and loss account with the share referring to the results for the year and directly in the equity with the share referring to entries directly on the equity.
The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).
Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities wich have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c1" xml:lang="en">Tangible assets
Tangible assets are measured at cost with deduction of accrued depreciation and writedown.
The depreciable amount is cost plus revaluations at fair value less expected residual value after the end of the useful life of the asset. The amortisation period is fixed at the acquisition date and reassessed annually. If the residual value exceeds the carrying mount of the asset, depreciation is discontinued.
If the amortisation period or the residual value is changed, the effect on amortisation will, in future, be recognised as a change in the accounting estimates.
The cost comprises acquisition cost and costs directly associated with the acquisition until the time when the asset is ready for use.
Depreciation is done on a straight-line basis according to an assessment of the expected useful life:
Other fixtures and fittings, tools and equipment Useful life 10 years</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><e:DescriptionOfMethodsOfLeases contextRef="c1" xml:lang="en">Leases
The enterprise is applying IFRS 16 as its basis of interpretation for the recognition of classification and recognition of leases.
Leases pertaining to property, plant, and equipment for which the enterprise has the right-of-use are recognised in the statement of financial position as right-of-use assets. The assets are, at initial recognition, measured at imputed cost, consisting of:
The imputed lease liability
Any lease payments paid prior to â or on â the starting date, less any lease incentives received
Any direct start-up costs
Any restoring costs
Hereafter, recognised leased assets are treated like the enterpriseâs remaining property, plant, and equipment.
Lease liabilities are recognised in the statement of financial position as liabilities other than provision and are measured, at initial recognition, at the present value of lease payments payable over the lease term. This includes a purchase option in the event that the enterprise expects to purchase the right-of-use asset. When determining the present value, the internal rate of return or, alternatively, the enterpriseâs borrowing rate is applied as discount rate.
Hereafter, the lease liability is treated like the remaining financial liabilities, i.e. at amortised cost.
The interest element of the lease payments is recognised in the income statement over the contractual term.
The following leases are not recognised as assets and liabilities in the statement of financial position:
Leases with a duration of twelve months or less (short leases)
Leases where the replacement value of the asset is less than DKK 30,000. (low-value assets)
For such leases, the lease payment is recognised in the income statement as an expense on a linear basis over the lease term.
</e:DescriptionOfMethodsOfLeases><e:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets contextRef="c1" xml:lang="en">Impairment loss relating to non-current assets
If there are indicators of impairment in tangible fixed assets, an impairment test will be performed.
If indications of impairment are disclosed, impairment tests are carried out for each individual asset or group of assets, respectively. Writedown for impairment is done to the recoverable amount if this value is lower than the carrying amount.
The recoverable amount is the higher value of value in use and selling price less expected selling cost. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the asset group and expected net cash flows from the sale of the asset or the asset group after the end of their useful life.
Previously recognised impairment losses are reversed when conditions for impairment no longer exist.
</e:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="c1" xml:lang="en">Receivables
Receivables are measured at amortised cost, which usually corresponds to nominal value. In order to meet expected losses, they are written down for impairment to the net realisable value.
An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on individual basis.
Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtor's domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.
Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="c1" xml:lang="en">Prepayments
Prepayments recognised under assets comprise incurred costs concerning the following financial year.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity contextRef="c1" xml:lang="en">Equity</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity><e:DescriptionOfMethodsOfDividends contextRef="c1" xml:lang="en">Dividend
Dividend expected to be distributed for the year is recognised as a separate item under equity.
</e:DescriptionOfMethodsOfDividends><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c1" xml:lang="en">Income tax and deferred tax
Current tax receivable and tax liabilities are recognised in the balance sheet at the amount calculated on the basis of the expected taxable income for the year adjusted for tax on previous year's taxable income and prepaid taxes. Tax receivable and tax liabilities are set off to the extent that legal right of set-off exists and if the items are expected to be settled net or simultaneously.
Deferred tax is measured on the basis of temporary differences in assets and liabilities with a balance sheet focus.
Deferred tax assets, including the tax value of tax losses eligible for carry-over, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit.
Deferred tax is measured based on the tax rules and tax rates applying under the legislation on the balance sheet date and prevailing when the deferred tax is expected to be released as current tax.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherProvisions contextRef="c1" xml:lang="en">Provisions
Provisions are measured at net realisable value or at fair value. If the fulfilment of a liability is expected to take place far in the future, the liability is measured at fair value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherProvisions><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="en">Liabilities other than provisions
Financial liabilities other than provisions related to borrowings are recognised at the received proceeds less transaction costs incurred. In subsequent periods, the financial liabilities are recognised at amortised cost, corresponding to the capitalised value when using the effective interest rate. The difference between the proceeds and the nominal value is recognised in the income statement during the term of the loan.
Other liabilities are measured at amortised cost which usually corresponds to the nominal value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><e:DisclosureOfDeferredTaxAssetsAndLiabilities contextRef="c1" xml:lang="en">8.
Deferred tax assets
Deferred tax assets 1 January 2023
7.912.426
7.644.886
Deferred tax of the results for the year
3.271.642
267.540
11.184.068
7.912.426
Deferred tax assets consist of fixtures and fittings, other plant and equipment and provisions.
</e:DisclosureOfDeferredTaxAssetsAndLiabilities><e:DisclosureOfContingentLiabilities contextRef="c1" xml:lang="en">14. Contingencies
Contingent liabilities
The company has issued a payment guarantee to the bank, which as of 31 December 2023 amounted to TDKK 3,163.
Novo Nordisk Denmark A/S is jointly taxed with the Danish companies in Novo Holdings A/S Group. The joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to income taxes and withholding taxes may lead to a larger liability. The tax for the individual companies is allocated in full on the basis of the expected taxable income.
</e:DisclosureOfContingentLiabilities><e:InformationOnRelatedEntities contextRef="c1" xml:lang="en">15. Related parties
Controlling interest
Related Party
Novo Nordisk Region Europe A/S Novo Alle 1 2880 Bagsværd Denmark
Basis for control
Principle shareholder owns 100 %
Information about consolidated Financial Statements
Parent
Novo Nordisk A/S Novo Alle 1 2880 Bagsværd
Denmark
Requisitioning of the parent company's consolidated Financial Statements:
www.novonordisk.dk
Novo Nordisk A/S is included in the consolidated financial statements of Novo Nordisk Foundation, Tuborg Havnevej 19, 2900 Hellerup.
Transactions
The Company solely discloses related party transactions that have not been carried out on an arm's length basis, cf. section 98c(7) of the Danish Financial Statements Act. All transactions have been carried out on an arm's length basis.
</e:InformationOnRelatedEntities><!--Aktuelle periode enkelt selskab--><context id="c1"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period></context><!--Forrige periode enkelt selskab--><context id="c2"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period></context><!--Slutdato forrige periode enkelt selskab--><context id="c3"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-12-31</instant></period></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c4"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period></context><!--BOARD1--><context id="c5"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfSupervisoryBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD2--><context id="c6"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfSupervisoryBoardDimension"><d:memberOfBoardIdentifier>2</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD3--><context id="c7"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfSupervisoryBoardDimension"><d:memberOfBoardIdentifier>3</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--CEO1--><context id="c29"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR1--><context id="c37"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>1</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR2--><context id="c38"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>2</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Grunde og bygninger aktuel primo--><context id="c84"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LandAndBuildingsMember</xbrldi:explicitMember></scenario></context><!--Grunde og bygninger aktuel i aaret--><context id="c88"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LandAndBuildingsMember</xbrldi:explicitMember></scenario></context><!--Grunde og bygninger aktuel ultimo--><context id="c89"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LandAndBuildingsMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel primo--><context id="c99"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel i aaret--><context id="c100"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel ultimo--><context id="c101"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Indretning lokaler aktuel primo--><context id="c105"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LeaseholdImprovementsMember</xbrldi:explicitMember></scenario></context><!--Indretning lokaler aktuel i aaret--><context id="c106"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LeaseholdImprovementsMember</xbrldi:explicitMember></scenario></context><!--Indretning lokaler aktuel ultimo--><context id="c107"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LeaseholdImprovementsMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel primo--><context id="c119"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c121"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c137"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c138"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c139"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Udbytte aktuel primo--><context id="c140"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte aktuel i aaret--><context id="c141"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte aktuel ultimo--><context id="c142"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--HTAL aar3--><context id="c184"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2002-01-01</startDate><endDate>2002-12-31</endDate></period></context><!--HTAL ultimo aar3--><context id="c186"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2002-12-31</instant></period></context><!--HTAL aar4--><context id="c187"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2001-01-01</startDate><endDate>2001-12-31</endDate></period></context><!--HTAL ultimo aar4--><context id="c189"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2001-12-31</instant></period></context><!--HTAL aar5--><context id="c190"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2000-01-01</startDate><endDate>2000-12-31</endDate></period></context><!--HTAL ultimo aar5--><context id="c192"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2000-12-31</instant></period></context><!--Gald LO aktuel ultimo--><context id="c254"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2023-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfLongTermLiabilitiesDimension">e:LongtermLeaseCommitmentsMember</xbrldi:explicitMember></scenario></context><!--HTAL VALG_1_1--><context id="c331"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>2</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HTAL VALG_1_2--><context id="c332"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>2</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HTAL VALG_1_3--><context id="c333"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2002-01-01</startDate><endDate>2002-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>2</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HTAL VALG_1_4--><context id="c334"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2001-01-01</startDate><endDate>2001-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>2</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HTAL VALG_1_5--><context id="c335"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2000-01-01</startDate><endDate>2000-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>2</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HPCT VALG_1_1--><context id="c381"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2023-01-01</startDate><endDate>2023-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>12</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HPCT VALG_1_2--><context id="c382"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>12</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HPCT VALG_1_3--><context id="c383"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2002-01-01</startDate><endDate>2002-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>12</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HPCT VALG_1_4--><context id="c384"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2001-01-01</startDate><endDate>2001-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>12</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--HPCT VALG_1_5--><context id="c385"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2000-01-01</startDate><endDate>2000-12-31</endDate></period><scenario><xbrldi:typedMember dimension="h:IdentificationOfKeyFigureOrFinancialRatioDimension"><h:keyFigureOrFinancialRatioIdentifier>12</h:keyFigureOrFinancialRatioIdentifier></xbrldi:typedMember></scenario></context><!--Virksomhedskapital forrige EKprimo--><context id="c478"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKultimo--><context id="c480"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKprimo--><context id="c498"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKi aaret--><context id="c499"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKultimo--><context id="c500"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Udbytte forrige EKprimo--><context id="c501"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-01-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte forrige EKi aaret--><context id="c502"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><startDate>2022-01-01</startDate><endDate>2022-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--Udbytte forrige EKultimo--><context id="c503"><entity><identifier scheme="http://www.dcca.dk/cvr">38180045</identifier></entity><period><instant>2022-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember></scenario></context><!--DKK enere--><unit id="u5"><measure>iso4217:DKK</measure></unit><!--Antal--><unit id="u7"><measure>xbrli:pure</measure></unit></xbrl>